Form 8-K - Current report:
SEC Accession No. 0001193125-22-207610
Filing Date
2022-08-01
Accepted
2022-08-01 06:09:05
Documents
14
Period of Report
2022-07-26
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d353433d8k.htm   iXBRL 8-K 27332
2 EX-99.1 d353433dex991.htm EX-99.1 15287
6 GRAPHIC g353433g0801020111815.jpg GRAPHIC 5408
  Complete submission text file 0001193125-22-207610.txt   183350

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cadl-20220726.xsd EX-101.SCH 2859
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cadl-20220726_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cadl-20220726_pre.xml EX-101.PRE 11709
8 EXTRACTED XBRL INSTANCE DOCUMENT d353433d8k_htm.xml XML 3548
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

EIN.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40629 | Film No.: 221122671
SIC: 2836 Biological Products, (No Diagnostic Substances)